Junquan Zeng

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 4

Top Topics

Ankylosing Spondylitis

Multiple Myeloma

Systemic Lupus Erythematosus

Vascular Endothelial Growth Factor

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Dan Huang, Zhipeng Wu, Zhengyi Wu, Nuoya Li, Liang Hao, Kuangfan Li, Junquan Zeng, Bingbing Qiu, Shou-Hua Zhang, Jinlong Yan
Enhanced Antipediatric Sarcoma Effect of Everolimus with Secukinumab by Targeting IL17A. Molecular cancer therapeutics 23 (5) (2024)
Dan Huang, Zhipeng Wu, Zhengyi Wu, Nuoya Li, Liang Hao, Kuangfan Li, Junquan Zeng, Bingbing Qiu, Shou-Hua Zhang, Jinlong Yan
Enhanced Antipediatric Sarcoma Effect of Everolimus with Secukinumab by Targeting IL17A. Molecular cancer therapeutics 23 (5) (2024)
Dan Huang, Zhipeng Wu, Zhengyi Wu, Nuoya Li, Liang Hao, Kuangfan Li, Junquan Zeng, Bingbing Qiu, Shou-Hua Zhang, Jinlong Yan
Enhanced Anti-Pediatric Sarcomas Effect of Everolimus with Secukinumab by Targeting IL-17A. Molecular cancer therapeutics (2024)
Wenfeng He, Yonghui Fu, Yongliang Zheng, Xiaoping Wang, Bin Liu, Junquan Zeng
Diallyl thiosulfinate enhanced the anti-cancer activity of dexamethasone in the side population cells of multiple myeloma by promoting miR-127-3p and deactivating the PI3K/AKT signaling pathway. BMC cancer 21 (1) (2021)